Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform
June 21 2024 - 6:50AM
Business Wire
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”,
HKEX: 02315) announced United States Patent and Trademark Office
(USPTO) patent grant for independently developed RenLite® fully
human common light chain mouse platform.
RenLite® mice, developed using Biocytogen’s proprietary
Size-Unlimited and Precise Chromosome Engineering (SUPCETM)
technology, feature the in situ replacement of the entire human
antibody heavy chain variable region genes and a single light chain
variable region gene. This enables the generation of highly diverse
fully human antibodies that share a common light chain, effectively
avoiding light-heavy chain mismatches during the assembly of
bispecific antibodies, thereby significantly reducing the
complexity of the CMC process. The molecular structures of these
bispecific antibodies resemble monoclonal antibodies, exhibiting
favorable physicochemical properties. Leveraging RenLite® and
RenLite® KO mice, Biocytogen has generated a library of antibodies
targeting over 200 TAA targets, enabling the rapid development of
bispecific antibody and bispecific antibody-drug-conjugate (ADC)
therapies.
In addition to the RenLite® platform, Biocytogen’s independently
developed RenMice® series includes RenMabTM, RenNano®, RenTCRTM and
RenTCR-mimicTM platforms. These five fully human antibody/TCR mouse
platforms cater to the diverse R&D needs of pharmaceutical
companies globally. Since their debut in 2019, the RenMice®
platforms have garnered widespread recognition within the biotech
and pharmaceutical industries. As of December 31, 2023, Biocytogen
has established 47 target-nominated RenMice® licensing projects
with over 20 multinational corporations (MNCs) and
biopharmaceutical/biotech companies, including Merck KGaA, Janssen,
Xencor, BeiGene and Innovent. The RenMice® platform has generated a
library of over 400,000 fully human antibodies against thousands of
targets and high-quality candidate antibodies, facilitating 103
projects encompassing co-development, out-licensing, and transfer
agreements.
The U.S. patent authorization for the RenLite® platform
technology demonstrates Biocytogen’s exceptional innovation
capabilities and global competitiveness. Biocytogen will continue
to pursue global patent strategies and protect key technologies,
offering advanced technology platforms and robust intellectual
property protection for its partners. Besides the United States,
patent applications for the RenLite® platform have been submitted
in China, Europe, Japan, South Korea, Canada, Singapore, Russia,
Israel, Australia, and other countries and regions with
authorizations in progress.
About Biocytogen Biocytogen (HKEX: 02315) is a global
biotechnology company that drives the research and development of
novel antibody-based drugs with innovative technologies. Founded on
gene editing technology, Biocytogen leverages genetically
engineered proprietary RenMice®
(RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully
human monoclonal/bispecific/multispecific antibody discovery,
bispecific antibody-drug conjugate discovery, nanobody discovery
and TCR-mimic antibody discovery, and has established a sub-brand,
RenBiologicsTM, to explore global partnerships for an off-the-shelf
library of >400,000 fully human antibody sequences against
approximately 1000 targets for worldwide collaboration. As of
December 31, 2023, 103 therapeutic antibody and multiple clinical
asset co-development/out-licensing/transfer agreements and 47
target-nominated RenMice® licensing projects have been established
around the globe, including several partnerships with multinational
pharmaceutical companies (MNCs). Biocytogen pioneered the
generation of drug target knock-in humanized models for preclinical
research, and currently provides a few thousand off-the-shelf
animal and cell models under the company’s sub-brand, BioMice®,
along with preclinical pharmacology and gene-editing services for
clients worldwide. Headquartered in Beijing, Biocytogen has
branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San
Francisco), and Germany (Heidelberg). For more information, please
visit http://en.biocytogen.com.cn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620000304/en/
Biocytogen Antibody assets and platforms:
BD-Licensing@biocytogen.com Press Contact: pr@bbctg.com.cn